Rocket Lab CEO Peter Beck Says Watch the Test Stands. Here's Why the Neutron Timeline Means Everything for Investors.

The key mechanism is not just schedule slippage; it is customer reallocation. In launch, “wait and see” only lasts until a credible alternative is flight-proven, and once a defense or commercial buyer qualifies another provider, that slot often stays with the incumbent alternative for years. That means RKLB’s valuation risk is less about this quarter’s revenue bridge and more about losing the medium-lift option value that justifies a premium multiple.

The second-order winners are the firms with either deeper balance sheets or faster path-to-flight credibility. NOC benefits if its partnered Eclipse program converts delay fatigue into procurement share, while SpaceX remains the default substitution point for any customer that cannot tolerate calendar risk; that pressure should also pull pricing discipline tighter across the whole launch stack. The underappreciated loser is not only RKLB launch revenue, but the cross-sell halo from satellite integration: if launch confidence erodes, integrated customers may still buy spacecraft subsystems, but they will decouple launch procurement earlier and more aggressively.

Contrarian view: the market may be over-penalizing the company if it is already being valued as a launch pure-play. The satellite systems franchise provides a floor, and one clean Neutron campaign can re-open the story quickly; the real falsifier for the bearish case is evidence of schedule recovery before competitors log a first flight. But if first meaningful Neutron flights slip beyond 1H27, the equity should re-rate toward a “services + small launch” profile, not a medium-lift platform premium.